Etiena Basner‐Tschakarjan1, Evelyn Gaffal1, Meredith O’Keeffe2, Damiá Tormo1, Percy A. Knolle3, Hermann Wagner4, Hubertus Hochrein2,4,5, Thomas Tüting1,5
1Laboratory of Experimental Dermatology, Department of Dermatology, University of Bonn, Germany
2Immunology Research, Bavarian Nordic, Martinsried, Germany
3Institute of Molecular Medicine and Experimental Immunology, University of Bonn, Germany
4Institute of Medical Microbiology, Immunology, and Hygiene, Technical University of Munich, Munich, Germany
5These authors share senior authorship.
Tóm tắt
AbstractBackgroundRecombinant replication‐deficient adenoviral vectors (recAd) are attractive candidates for DNA vaccination approaches because they are able to activate the innate and adaptive immune systems. Here we explore the ability of recAd to transduce and activate subsets of dendritic cells, namely plasmacytoid dendritic cells (pDC) and conventional dendritic cells (cDC).MethodsDC were derived from bone marrow precursors in vitro with the help of FLT3‐ligand. Sorted populations of pDC and cDC were infected with recAd at various multiplicities of infection. Transduction efficiency, phenotypic maturation and production of IFN‐α as well as IL‐6 were assessed. Additionally, activation of DC and induction of cytotoxic T lymphocytes (CTL) were determined in vivo. The role of Toll‐like receptor (TLR) 9 in recAd recognition was investigated as it has previously been shown that DNA viruses are recognized via this receptor.ResultsRecAd can efficiently transduce pDC as well as cDC in vitro. Both DC subsets mature and produce IFN‐α upon interaction with recAd. In the absence of TLR9, activation and cytokine production was only detected in cDC but not in pDC. Importantly, induction of CD8+ CTL following in vivo injection of recAd was similar in TRL9‐deficient mice when compared with wildtype controls.ConclusionsRecAd can efficiently transduce and activate both pDC and cDC. pDC required TLR9 to detect the presence of recAd whereas cDC also recognized recAd independently of TLR9. These unique immunostimulatory properties support the future development of recombinant Ad as a vector for DNA vaccine approaches. Copyright © 2006 John Wiley & Sons, Ltd.
